Matinas BioPharma
MTNB
21 hedge funds and large institutions have $254K invested in Matinas BioPharma in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0.86% less ownership
Funds ownership: 6.29% → 5.43% (-0.86%)
5% less funds holding
Funds holding: 22 → 21 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
72% less capital inflows, than outflows
Capital inflows: $8.38K | Capital outflows: $30.4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.42K |
| 2 |
Renaissance Technologies
New York
|
+$1.69K |
| 3 |
Raymond James Financial
St Petersburg,
Florida
|
+$231 |
| 4 |
Jones Financial Companies
Des Peres,
Missouri
|
+$44 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13.3K |
| 2 |
Two Sigma Securities
New York
|
-$10.9K |
| 3 |
Sargent Investment Group
Bethesda,
Maryland
|
-$4.53K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.12K |
| 5 |
JP Morgan Chase
New York
|
-$470 |
MTNB Hedge Fund Activity: Q2 2025 in Review
21 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2025, worth a combined $254K — up 53% from $166K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of MTNB and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 2 added.
The largest buyer was Geode Capital Management, adding an estimated $6.42K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $13.3K sold.
- 21 institutional investors held Matinas BioPharma (MTNB) as of Q2 2025, down from 22 in Q1 2025.
- Funds reported $254K of Matinas BioPharma stock for Q2 2025, up 53% quarter-over-quarter.
- 2 funds opened new Matinas BioPharma positions in Q2 2025 and 3 closed out, a net change of -1 holder.
- The largest Matinas BioPharma buyer in Q2 2025 was Geode Capital Management, an estimated $6.42K added.
- The largest Matinas BioPharma seller in Q2 2025 was Susquehanna International Group, an estimated $13.3K sold.
Based on aggregated 13F filings for Q2 2025.